Trial
NCT04582669
Optimizing Intralesional Triamcinolone Dosing for Hidradenitis Suppurativa
Phase IVTERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Montefiore Medical Center
Collaborators
—
Condition
Hidradenitis Suppurativa
Intervention
Intralesional Triamcinolone 10 mg/mL
Why stopped
This study was administratively closed.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-11-13